论文部分内容阅读
目的:评价布地奈德雾化吸入疗法对新生儿感染性肺炎患者的临床疗效。方法:选取2014年1月—2015年2月间收治的新生儿感染性肺炎患者70例作为研究对象;将其分为治疗组患者和对照组患者,各35例;对照组患者均给予常规治疗,治疗组患者在对照组治疗基础上均给予布地奈德雾化吸入治疗,比较两组患者的总有效率、住院时间和复发率。结果:治疗组患者治疗后的总有效率为97.14%显著高于对照组为82.86%(P<0.05);治疗组患者复发1例,平均住院时间为(7.2±2.8)d和复发1例,优于对照组为(12.1±3.1)d和复发为9例(P<0.05)。结论:布地奈德雾化吸入疗法是一种有效治疗新生儿感染性肺炎患者的治疗方案,该方法治疗效果显著,临床治疗过程中未发现严重不良反应。
Objective: To evaluate the clinical efficacy of budesonide inhalation therapy in neonatal pneumonia. Methods: Seventy patients with neonatal infectious pneumonia admitted from January 2014 to February 2015 were selected as the research object. The patients were divided into treatment group and control group, 35 cases in each. Patients in the control group were given routine treatment The patients in the treatment group were given budesonide inhalation therapy on the basis of the control group, and the total effective rate, hospitalization time and recurrence rate were compared between the two groups. Results: The total effective rate of the treatment group was 97.14%, which was significantly higher than that of the control group (82.86%, P <0.05). One case was recurred in the treatment group, the average length of stay was (7.2 ± 2.8) days and the recurrence was found in 1 case It was superior to the control group (12.1 ± 3.1) d and recurrence was 9 (P <0.05). Conclusion: Budesonide inhalation therapy is an effective treatment for neonatal pneumonia patients. The treatment is effective and no serious adverse reactions are found during the course of clinical treatment.